🇮🇪Ireland
16°C Partly Cloudy · Dublin
Live Updates
--:--:-- IST
Contributor sign in
Latest
Clinical Trials in Egypt / NCT07302815
Active, not recruiting Not applicable

Preemptive Intravenous Micro-dose Dexmedetomidine to Prevent Emergence Agitation in Adult Patients Undergoing Septoplasty Surgeries

NCT07302815 · tracked via the Priya Life Science Egypt tracker
Phase
Not applicable
Started
2026-01-10
Last updated
2026-05-06

Condition(s) studied

Emergence Agitation

Investigational drug(s) / intervention(s)

Dexmedetomidine →Saline

Dexmedetomidine: micro dose of dexmedetomidine (0.3 µg /kg) in 50 ml 0.9% saline slow infusion over 10 minutes, 15 minutes before surgery.

Saline: 50 ml 0.9% saline slow infusion over 10 minutes, 15 minutes before surgery.

Study summary

This prospective randomized controlled study will be conducted to evaluate the effect of preoperative single, micro-dose of dexmedetomidine (0.3μg/kg) on the incidence and severity of EA in adults undergoing Septoplasty surgeries

Eligibility

Sex
ALL
Min age
18 Years
Max age
60 Years
Healthy volunteers
No
Inclusion Criteria: * Adult patients of both gender aged 18 to 60 years with American Society of Anesthesiologists (ASA) Physical Status I or II, who were scheduled for septoplasty surgery under general anesthesia. Exclusion Criteria: * Patients declined to participate in the trial. * History or clinical evidence of chronic obstructive pulmonary disease. * History of renal or hepatic dysfunction, sleep apnea syndrome. * Cognitive dysfunction or psychiatric disorder. * Patients receiving beta blocker. * Patients with anticipated difficult airway. * Patients with electro cardiac abnormalities. * Emergency surgeries. * Pregnancy.

Primary outcome measure(s)

Trial sites (1)

FacilityCityRegionStatus
Tanta university Tanta Gharbia Governorate

More Tanta University trials in Egypt

Other trials for the same condition

Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT07302815 on ClinicalTrials.gov ↗ ← All trials in Egypt